Abstracts

Picker N, Bokemeyer B, Wilke T, Rosin L, Patel H. ECCO Abstract 2021: P404 Healthcare utilization and expenditures for patients with Ulcerative Colitis on advanced therapies in Germany (2021). Journal of Crohn's and Colitis;15:411–412. https://doi.org/10.1093/ecco-jcc/jjab076.528.

Picker N, Patel H, Wilke T, Rosin L, Bokemeyer B. ECCO Abstract 2021: P423 Treatment escalation and associated cost in German Ulcerative Colitis patients treated with advanced therapies (2021). Journal of Crohn's and Colitis;15:427. https://doi.org/10.1093/ecco-jcc/jjab076.547.

Bokemeyer B, Plachta-Danielzik S, Di Giuseppe R, Mohl W, Teich N, Hoffstadt M, Schweitzer A, von der Ohe M, A Gauss, R Atreya, T Krause, I Blumenstein, J Höchstödter, P Hartmann, S Schreiber S. ECCO Abstract and oral presentation 2021: DOP47 Real World Evidence on the effectiveness of ustekinumab in Crohn’s Disease: Induction phase results from the prospective, observational RUN-CD Study 82021). Journal of Crohn's and Colitis;15:83–84. https://doi.org/10.1093/ecco-jcc/jjab073.086. 

Bokemeyer B, Kaiser C, Primas C, Novacek G, Biedermann L, Seibold F, Tappe U, Bettenworth D, Graw J, Hartmann P, Plachta-Danielzik S, Schultz C. ECCO Abstract 2021: P279 Potential of managed care programmes for patients with inflammatory bowel diseases – results from a large survey study among physicians and IBD-patients in Germany, Austria and Switzerland (the EASE-IBD study) (2021). Journal of Crohn's and Colitis; 15:310–313. https://doi.org/10.1093/ecco-jcc/jjab076.404.

RaineT, Bokemeyer B, Finney-Hayward T, Munsaka M, Liu M, Louis E. ECCO Abstract 2021: P468 Analysis of international spontaneous reporting system databases for safety of corticosteroids in Inflammatory Bowel Disease: The Determinants, Incidence and consequences of Corticosteroid Excess (DICE)-impact study (2021). Journal of Crohn's and Colitis; 15:458–459. https://doi.org/10.1093/ecco-jcc/jjab076.591.

Bokemeyer B, Picker N, Wilke T, Rosin L, Patel H. ECCO Abstract 2021: P377 Inadequate response with advanced therapies in real-world patients with Ulcerative Colitis – Results of a German claims database study. Journal of Crohn's and Colitis 2021;15:392. https://doi.org/10.1093/ecco-jcc/jjab076.501.

Bokemeyer B, Picker N, Wilke T, Rosin L, Patel H. ECCO Abstract 2021: P464 Steroid dependency in patients with Ulcerative Colitis treated with advanced therapies in a German real-world-setting (2021). Journal of Crohn's and Colitis 2021;15:455–456. https://doi.org/10.1093/ecco-jcc/jjab076.587.

Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Mohl W, Teich N, Hoffstadt M, Schweitzer A, von der Ohe M, Gauss A, Atreya R, Krause T, Blumenstein I, Hoechstoedter J, Hartmann P, Schreiber S. 526 PROPENSITY SCORE ADJUSTED QUALITY OF LIFE AND EFFECTIVENESS OF USTEKINUMAB INDUCTION THERAPY IN CROHN'S DISEASE: RESULTS OF THE RUN-CD STUDY (2021). DDW Abstract 2021;106-107 DOI:https://doi.org/10.1016/S0016-5085(21)01000-3.

Rosati E, Pogorelyy MV, Fazio AAMA, Dowds M, Lebedev YB, Schreiber S, Moller FT, Soerensen SB, Huebenthal M, Degenhardt F, Wendorff M, Lieb W, Bokemeyer B, Andersen V, Spehlmann ME, Mamedov IZ, Bacher P, Franke A. Unveiling disease-associated markers in the peripheral T-cell receptor (TCR) repertoire of inflammatory bowel disease (IBD) patients (2020). http://www.ikmb.uni-kiel.de.

Bokemeyer B, Baas S, Blömacher M, Koletzko S, Schuppan D. German Celiac Registry (GeCeR) - Untersuchung der Lebensqualität und psychosozialen Belastung bei Zöliakie (2020). Z Gastroenterol 2020;58: e151, DOI: 10.1055/s-0040-1716137.

Bokemeyer B, Plachta-Danielzik S,  Sobotzki C,  Mohl W,  Hoffstadt M,  Krause T, Atreya R,  von der Ohe M,  Graefe U,  Trentmann L,  Eisold M,  Linde A, Franzenburg S,  Moser M,  Hartmann P,  Schreiber S German IBD Study Group (GISG). P726 Effectiveness of vedolizumab therapy in a real-world setting in Germany: First results of the VEDOibd study comparing vedolizumab to the use of other biologics (2020). Journal of Crohn's and Colitis 2020.14584. https://doi.org/10.1093/ecco-jcc/jjz203.854. 

Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S. Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis (2018). Inflamm Bowel Dis. 2018 Oct 25. doi: 10.1093/ibd/izy323. 

Bokemeyer B, Plachta-Danielzik S, Teich N, Mohl W, Hoffstadt M, Schweitzer A, von der Ohe M, Krause T, Höchstödter J, Hartmann P, Wiebe B, Schreiber S. P728 Effectiveness and quality of life (QoL) of Ustekinumab (UST) therapy in a Real-world Setting in Germany – First Results of the RUN-CD Study. Poster presentation: Clinical: Therapy and observation (2019). Journal of Crohn’s and Colitis 2019.13:486.

Bokemeyer B, Hlavaty T, Allez M, Selema P, Moosavi S, Cadatal MJ, Fowler H, Cheung R, Lukas M, Gisbert JP. P590 An interim analysis of real-world safety data from an ongoing, non-interventional, observational study of patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar, in the context of usual care with reference infliximab (2019). Poster presentation: Clinical: therapy and observation (2019). Journal of Crohn’s and Colitis 2019.13:410.

Groth A, Brandes A, Fuchs A, Deiters B, Ratsch B, Wilke T, Bokemeyer B. Identification of Dose Escalation in Biologic Therapy Based on Claims Data: The Example of Patients with Inflammatory Bowel Disease. 

Bokemeyer B, Atreya R, Büning J, Kühbacher T, Maaser C, Wiebe B, Schmidt K, Hartmann P. Anti-TNF alpha Therapy in Biologics-naϊve Ulcerative Colitis Patients in a prospective “Real World” Study in Germany (BioColitis-Registry). Journal of Crohns & Colitis, 10 . S292-S293.

Schreiber S, Dietz L, Deuring J, Bokemeyer B. DGVS Jahrestagung Oktober 2019 Abstract und Vortrag: Persönlicher Eindruck und Prioritätensetzung von Patienten und Ärzten in der Patienten-Arzt-Kommunikation im Management der Colitis ulcerosa: Teilergebnisse der UC Narrative Umfrage in Deutschland(2019). ZfG 2019.

Bokemeyer B, Ghiani M, Fuchs A, Deiters B, Hardtstock F, Brandes A, Knop J, Orzechowski HD, Wilke T. DGVS Jahrestagung Oktober 2019 Abstract und Vortrag: Analyse von Real-World-Daten zur Krankheitsaktivität von Patienten mit chronisch entzündlichen Darmerkrankungen ohne Biologika-Therapie – COCOS Studie (2019). ZfG 2019.

Ghiani M, Naessens D, Takács P, Myers D, Maywald U, Bokemeyer B, Wilke T. PGI58 A STUDY OF LONG TERM HOSPITALIZATION COSTS IN PATIENTS WITH ULCERATIVE COLITIS USING GERMAN CLAIMS DATA (2021). 7 Value in Health 2019:22:626.

Ghiani M, Naessens D, Takacs P, Myers D, Maywald U, Bokemeyer B, Wilke T. 850 Long-Term Consequences of Surgery in Patients With Ulcerative Colitis: A Study Using German Claims Data, , Abstract American College of gastroenterology 2019. The American Journal of Gastroenterology; 114:491. doi: 10.14309/01.ajg.0000592936.64009.e3.

Rivas MA, Avila BE, Koskela J, Huang H, Stevens C, Pirinen M, Haritunians T, Neale BM, Kurki M, Ganna A, Graham D, Glaser B, Peter I, Atzmon G, Barzilai N, Levine AP, Schiff E, Pontikos N, Weisburd B, Lek M, Karczewski KJ, Bloom J, Minikel EV, Petersen BS, Beaugerie L, Seksik P, Cosnes J, Schreiber S, Bokemeyer B, Bethge J; International IBD Genetics Consortium; NIDDK IBD Genetics Consortium; T2D-GENES Consortium, Heap G, Ahmad T, Plagnol V, Segal AW, Targan S, Turner D, Saavalainen P, Farkkila M, Kontula K, Palotie A, Brant SR, Duerr RH, Silverberg MS, Rioux JD, Weersma RK, Franke A, Jostins L, Anderson CA, Barrett JC, MacArthur DG, Jalas C, Sokol H, Xavier RJ, Pulver A, Cho JH, McGovern DPB, Daly MJ. Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population (2018). PLoS Genet 2018;14:e1007329.

Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S. Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis (2018). Inflamm Bowel Dis. 2018 Oct 25. doi: 10.1093/ibd/izy323.

Bokemeyer B, Schweitzer A, Atreya R, Büning J, Maaser C, Krummenerl A, Lügering A, Jessen P, Schmidt K, Hartmann P, Wiebe B, Schreiber S. Biologika-Therapie bei Colitis ulcerosa im prospektiven „Real World Setting“ (BioColitis-Register): Klinische Wirksamkeit bei Biologika-naiven vs. Nicht naiven CU-Patienten. https://eref.thieme.de/ejournals/1439-7803_2018_08

Lindsay JO, Armuzzi A, Gisbert JP, Bokemeyer B, Peyrin-Biroulet L, Nguyen GC, Smyth M, Patel H. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease(2017). Dig Liver Dis. 2017 Aug 1. pii: S1590-8658(17)30985-4. doi: 10.1016/j.dld.2017.07.010.

Bokemeyer B, Krummenerl T, Maaser C, Büning J, Atreya R, Lügering A, Helwig U, Jessen P, Hartmann P, Schreiber S. Anti-TNF-alpha as Induction and Maintenance Therapy in Ulcerative Colitis Patientes in the BioColitis Registry in Germany. Poster presentations: Clinical: Therapy & observation (2016).

Groth A, Wilke T, Brandes A, Ratsch B, Fuchs A, Deiters B, Bokemeyer B. P635 Real-world treatment persistence and associatet costs with biologic therapy in patients with inflammatory bowel disease (IBD): Results of a retrospective cohort analysis of 1,149 patients treated in Germany. Journal of Crohn’s and Colitis 2018. 12:431.

Groht A, Wilke T, Brandes A, Ratsch B, Fuchs A, Deiters B, Bokemeyer B. PS155 Biologika zur Behandlung von Patienten mit chronisch-entzündlichen Darmerkrankungen (CED): Therapiekontinuität und assoziierte Arzneimittelkosten. 124. Kongress der Deutschen Gesellschaft für innere Medizin 2018.

Schmidt C, Baumgart D, Bokemeyer B, Büning C, Howaldt S, Stallmach A, Singfield C, Tremblay G, Jones T. P478 Traetment with ferric maltol associated with improvements in quality of life for IBD patients with iron deficiency anaemia. Journal of Crohn’s and Colitis 2018. 12:346.

Hardi R, Bokemeyer B, Sandborn W, Reinisch W, Shafran I, Stallmach A, Ehehalt R, Geransar P, Khalid JM, Tudor D, Schreiber S. P738 Sustained clinical remission with Vedolizumab in Moderate-to-Severe Crohn’s disease: A GEMINI 2 post hoc analysis of Week 14 remitters. Journal of Crohn’s and Colitis 2018. 12:485.

Kruis W, Leifeld L, Hoepffner N, Hoesl M, Jessen P, Mroß M, Klugmann T, Ceplis-Kastner S, Reimers B, Bokemeyer B. P0349. A prospective study to predict a mild course of Crohn’s disease an interim analysis oft the prognos study (2017). Gastroenterology 2018.152:377.

Wittig BM, Sabat R, Holzlöhner P, Witte-Händel E, Heilmann K, Witte K, Triebus J, Tzankov A, Laman JD, Bokemeyer B, Terracciano L, Schwärzler C, Kohler H, Volkmer R, Loddenkemper C, Wolk K, Hoffmann U, Günthert U. Absence of specific alternatively spliced exon of CD44 in macrophages prevents colitis(2017). Mucosal Immunol. 2017. doi: 10.1038/mi.2017.98.

Siegel, CA, Lichtenstein G, Siegmund B, Lewis JD, Wolf D, Luous E, Sebastian S, Hebuterne X, Bell A, Södermann C, Schuber S, Atreya R, Polyak S, Hoque S, Krummenerl A, Bokemeyer B, Krummenerl T, Shulmann S, Karlén P, Moum B, Dolin P. P501 Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02) 2017. J Crohns Colitis; 11: S333-S334.

Stallmach A, Bokemeyer B, Axler J, Curtis R, Ehehalt R, Feagan B, Geransar P, James A, Kaviya A, Khalid JM0, Wolf D, Schreiber S(2017). DOP026 Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remitters. DOP Session 3 - Vedolizumab and ustekinumab therapies 2017.

Schröder AS, Lennartz J, Wiebe B, Helwig U, Teich N, Schmidt C, Schreiber S, Bokemeyer B. Der frühe Morbus Crohn im Langzeitverlauf – Ergebnisse einer prospektiven „Real-World“ Inzidenzkohorte in Deutschland (BioCrohn-Register). Oral Präsentation bei DGVS-Kongress 2017. Z Gastroenterol, 2017. 55(08): p. KV 540.

Lennartz J, Schröder AS, Wiebe B, Helwig U, Teich N, Schmidt C, Schreiber S, Bokemeyer B. Anti-TNF-alpha Langzeittherapie bei Morbus Crohn – eine prospektive „Real-World” Observationsstudie in Deutschland (BioCrohn-Register). Oral Präsentation bei DGVS-Kongress 2017. Z Gastroenterol, 2017. 55(08): p. KV 542.

Bokemeyer B, Dignaß A, Schreiber S (2017). Biosimilars in Inflammatory Bowel Disease (IBD): Experiences and perceptions of german gastroenterologists. Z Gastroenterol. 2017;doi: 10.1055/s-0042-121520.

Peyrin-Biroulet L, Armuzzi A, Gisbert JP, Nguyen GC, Bokemeyer B, Lindsay J, Smyth M, Munsaka M, Ramagopalan S, Khalid JM. OP008. Predictors of NON-Response or loss of response to tumour necrosis factor antagonist therapies in inflammatory bowel disease (2016). United European Gastroenterology Journal 4 Supplement 1;4.

Armuzzi A, Lindsay J, Patel H, Bokemeyer B, Gisbert J P, Nguyen GC, Peyrin-Biroulet L, Smyth M, Khalid JM. P0308. The Incidence of and time to suboptimal therapy among patients with ulcerative Colitis and Crohn’s Disease initiating tumour necrosis factor Antagonists: A multi-country chart review (2016). United European Gastroenterology Journal 4 Supplement 1;263.

Lindsay J, Gibert JP, Patel H, Peyrin-Biroulet L, Armuzzi A, Bokemeyer B, Nguyen GC, Pree I, Khalid M. P0870 The incidence of suboptimal therapy after initiating a second tumour necrosis factor antagonist in patients with ulcerative colitis: A multi-country chart review (2016). United European Gastroenterology Journal 4 Supplement 1;452.

Bokemeyer B, Langbrandtner J, Jessen P, Büning J, Schreiber S, Raspe H, Hueppe A. M01865 Patient reported outcomes in a managed care project with inflammatory bowel disease patients in Germany:CEDnetz-Study (2016).gastrojournal 2016; 150: 799.

Schmidt C, Bokemeyer B, Fischer I, Helwig U, Lügering A, Teich N, Lang D, Rath S, Wittig B, Stallmach A. KV035 – Klinische Prädiktoren für einen komplizierten Verlauf bei Morbus Crohn: EPIC, eine deutschlandweite, prospektive, multizentrische Beobachtungsstudie (2016). Z Gastroenterol 2016; 54-KV035.

Bokemeyer B, Schreiber S (2016). Biosimilars im Einsatz zur Behandlung von Morbus Crohn und Colitis ulcerosa. Versorgungsfokus CED. Arbeitsgemeinschaft probiosimilars. www. Probiosimilars.de 2016.

Bokemeyer B, Krummenerl T, Maaser C, Büning J, Atreya R, Lügering A, Helwig U, Jessen P, Hartmann P, Schreiber S. P386 Anti-TNF alpha as induction and maintenance therapy in ulcerative colitis patients in the BioColitis Registry in Germany (2016). Poster presentations: Clinical: Therapy & observation (2016).

Dietrich N.-A, Baer F, Dignass A, Bokemeyer B, Fellermann K, Buening J. P579 Combined therapy of tacrolimus and vedolizumab in severe refractory ulcerative colitis (2016). Poster presentations: Clinical: Therapy & observation (2016).

Blumenstein I, Atreya R, Greger G, Bokemeyer B, Nurwakagari P, Neurath M. F, Wittig B (2016). P114 Predictors of clinical response during adalimumab therapy in Crohn’s disease patients: a German non-interventional study. Poster presentations: Clinical: Diagnosis & outcome (2016).

Bokemeyer B, Langbrandtner J, Jessen P, Büning J, Schreiber S, Raspe H, Hüppe A. Treatment patterns in a managed care project with Inflammatory Bowel Diesease patients in Germany: CEDnetz-Study. Poster presentations: Clinical: Diagnosis & outcome (2016).

Blumenstein I, Atreya R, Greger G, Bokemeyer B, Nurwakagari P, Neurath M. F., Wittig B. Predictors of clinical response during adalimumab therapy in Crohn’s disease patients: a German non-interventional study. Poster presentations: Clinical: Diagnosis & outcome (2016).

Teich N, Bokemeyer B, Mohl W, Walldorf J, Bruns T, Schmidt C, Stallmach A, German IBD Study Group (2016). Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD. Gut 2016; pii: gutjnl-2016-313138. doi: 10.1136/gutjnl-2016-313138.

Sternkopf J, Bokemeyer B, Tappe U, Schultz C. Physicains‘ Acceptance of Managed Care for Inflammatory Bowel Disease Patients in Germany (2016).

Armuzzi A, Lindsay J O, Mody R, Bokemeyer B, Gisbert J P, Peurin-Biroulet L, Nguyen GC, Siebenaler J, Äkerborg Ö, Smyth M (2015). P0346. Indicators of suboptimal therapy among Crohn’s disease patients treatet with tumor necrosis factor antagonists: results from al multinational study. United European Gastroenterology Week (UEGW) 2015.

Baumgart DC, Atreya R, Bachmann O, Bläker M, Bokemeyer B, Börner N, Büning J, Dignass A, Drabik A, Ehehalt R, Fischer A, Hartmann F, Hartmann H, Howaldt S, Grimm P, Krummenerl T, Kühbacher T, Lügering A, Maul J, Mross M, Neurath M, Nikolaus S, Preiss J, Reinshagen M, Schmelz R, Schmidt C, Schreiber S, Siegmung B, Stallmach A, Teich N, Von Arnim U (2015). OP053. Verdolizumab for inflammatory bowel disease in clinical practice – experience from a prospective german registry. United European Gastroenterology Week (UEGW) 2015.

Lindsay J O, Gibert JP, Mody R, Peyrin-Biroulet L, Armuzzi A, Bokemeyer B, Nguyen GC, Siebenaler J, Äkerborg Ö, Smyth M (2015). P0963 A multinational study to determine indicators of suboptimal therapy among ulcerative colitis patients treated with tumor nekrosis factor antagonists. Poster presentations: United European Gastroenterology Week (UEGW) 2015.

Bokemeyer B, Langbrandtner J, Jessen P, Büning J, Schreiber S, Raspe H, Hüppe A (2015). P559 Improving Health Care of Patients with Inflammatory Bowel Diseases (IBD) by Fostering Networking of Physicians - it´s not that easy. Poster presentations: Clinical: Therapy & observation. Journal of Crohn’s and Colitis 2015; Volume9/S1:359-360.

Bokemeyer B, Krummenerl A, Maaser C, Howaldt S, Mroß M, Mallard N (2015). P581 A Pharmacokinetic Study of Ferric Maltol (ST10; Fe-M) at 3 Dosages in Inflammatory Bowel Disease (IBD) Patients with Iron Deficiency. Poster presentations: Clinical: Therapy & observation. Journal of Crohn’s and Colitis 2015; Volume9/S1:370.

Lühr, D., Bokemeyer, B., Helwig, U., Maaser, C., Jessen, P., Schreiber, S. (2015): Small bowel capsule endoscopy in ulcerative colitis – the capcolitis study: a prospective observational study in Germany. Poster bei der UEGW 2015. UEG Journal; Vol.3 (Suppl.5), A 241-242. 

Büning C, Ahmad T, Bokemeyer B, Cummings F (2015). P521 Correcting iron deficiency anaemia in IBD with oral ferric maltol: Use of proton pump inhibitors does not affect efficacy. Poster presentations: Clinical: Therapy & observation. Journal of Crohn’s and Colitis 2015; Volume9/S1:370.

Schmidt C, Bokemeyer B, Helwig U, Luegering A, Teich N, Engel K, Rath S, Wittig BM, Stallmach A (2015). 1DOP059 Clinical predictive parameters for severe Crohn's disease in real-life: Results from EPIC, a nation-wide prospective observational study. Poster presentations: Clinical: Therapy & observation. Journal of Crohn’s and Colitis 2015; Volume9/S1:58.